Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8+ T Cell Transcriptional Programs

Laura Spinelli, Julia M. Marchingo, Aneela Nomura†, Marcos P. Damasio† and Doreen A. Cantrell*

Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom

Phosphoinositide 3-kinase p110 delta (PI3K p110δ) is pivotal for CD8+ T cell immune responses. The current study explores PI3K p110δ induction and repression of antigen receptor and cytokine regulated programs to inform how PI3K p110δ directs CD8+ T cell fate. The studies force a revision of the concept that PI3K p110δ controls metabolic pathways in T cells and reveal major differences in PI3K p110δ regulated transcriptional programs between naïve and effector cytotoxic T cells (CTL). These differences include differential control of the expression of cytolytic effector molecules and costimulatory receptors. Key insights from the work include that PI3K p110δ signalling pathways repress expression of the critical inhibitory receptors CTLA4 and SLAMF6 in CTL. Moreover, in both naïve and effector T cells the dominant role for PI3K p110δ is to restrain the production of the chemokines that orchestrate communication between adaptive and innate immune cells. The study provides a comprehensive resource for understanding how PI3K p110δ uses multiple processes mediated by Protein Kinase B/AKT, FOXO1 dependent and independent mechanisms and mitogen-activated protein kinases (MAPK) to direct CD8+ T cell fate.

Keywords: PI3K, p110δ, CD8+ T cells, TCR signalling, transcriptomics, cytokines, chemokines

INTRODUCTION

CD8+ cytotoxic T cells are critical cells for mammalian adaptive immune responses that clear pathogen infected cells. The proliferation and differentiation of CD8+ T cells into cytolytic effector cells (CTL) is directed by an integrated network of signals driven by the T cell antigen receptor (TCR) and modulated by cytokines and cytokine receptors and costimulatory and inhibitory receptors (1, 2). One rapid consequence of TCR engagement in CD8+ T cells is the production of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), the product of phosphoinositide 3-kinase (PI3K). CD8+ T cells thus rapidly accumulate PtdIns(3,4,5)P3 following TCR engagement (3–5) and sustain high levels of PtdIns(3,4,5)P3 as they differentiate to effector CTL (6, 7). Cellular levels of PtdIns(3,4,5)P3 in T cells are controlled by a PI3K complex that contains the p110δ catalytic...
subunit (PI3K p110δ) (4, 8, 9). The importance of PI3K p110δ is emphasised by the discovery that both loss and gain of function mutations of PI3K p110δ cause primary immunodeficiency and autoimmunity in humans and mice (10–13). Effective PI3K p110δ inhibitors, used clinically to treat immune dysfunction and cancer, are available (14–17).

The importance of PI3K p110δ for T cells makes it important to understand the molecular details of how it controls T cell function. In this context, PtdIns(3,4,5) and cancer, are available (14,15) to maintain CD8+ T cell effector function (23). In this context, PI3K p110δ controls the activity of the serine/threonine kinase PKB/akt which phosphorylates the transcription factor FOXO1 causing its exclusion from the nucleus and terminating FOXO1 controlled transcription. In naïve T cells, FOXO1 controls expression of transcription factors and cytokine receptors that maintain T cell quiescence (18). FOXO1 also controls expression of the adhesion molecules and chemokine receptors that instruct T cell trafficking to secondary lymphoid tissue (19–21). In pathogen activated and effector CTL, PI3K p110δ signalling keeps FOXO1 cytosolic and inactive (22) to maintain CD8⁺ T cell effector function (23). The loss of PKB/akt activity causes nuclear relocation of FOXO1 resulting in the induction of the transcriptional program required for memory T cells (18, 23). FOXO1 is thus essential for memory CD8⁺ T cell formation and maintenance (24–27) and may control T cell exhaustion during chronic viral infections by to controlling the expression of the inhibitory receptor PD-1 and regulating T cell survival (28).

FOXO1 studies have given important insights about how PI3K p110δ controls CD8⁺ T cells but it is pertinent that PI3K p110δ signalling pathways go beyond the control of FOXO1. There are thus multiple substrates for PKB/akt and PI3K p110δ also modulates the activity of mitogen-activated protein (MAP) kinases (29, 30). Furthermore, there has never been an unbiased analysis or direct comparison of how PI3K p110δ shapes transcriptomes and proteomes in naïve versus effector CD8⁺ T cells. In this respect, signal transduction outcomes can be shaped by the epigenetic and metabolic remodelling that accompanies T cell differentiation. Hence in naïve T cells the role of the TCR is to initiate expression of biosynthetic and transcriptional programs that drive T cell clonal expansion and differentiation. In effector CD8⁺ T cells these programs are controlled by pro-inflammatory cytokines and the role of the TCR is to trigger execution of effector function (e.g. the production of cytokines and degranulation of cytolytic effector molecules).

Accordingly, the current objective was to use RNA sequencing, proteomic and secretome analysis to define the contribution of PI3K p110δ to antigen receptor regulated programs in naïve and effector CD8⁺ T cells. For mechanistic insights, we examined PI3K p110δ controlled responses in wild type (WT) and FOXO1 null effector CTL to understand how much of PI3K signalling is directed by FOXO1. We also assessed the importance of PKB/akt and the MAP kinases as mediators of PI3K p110δ responses. This work provides a comprehensive understanding of the targets for PI3K p110δ signals in antigen receptor activated naïve and effector CD8⁺ T cells and creates the information framework necessary to predict the implications of the therapeutic manipulation of PI3K p110δ for CD8⁺ T cells.

### MATERIALS AND METHODS

#### Mice

For naïve and 24 h activated CD8⁺ T cells ± PI3K p110δ inhibitor, unstimulated and 4 h TCR activated CTL ± PI3K p110δ inhibitor transcriptomes, P14 transgenic mice (31) were used (female mice, 9–13 weeks old).

FOXO1-GFP/fl mice were generated at Taconic. To allow conditional deletion of FOXO1, exon 2, which includes the EGFP sequence, was flanked by LoxP sites (32). Then to allow the deletion of FOXO1-GFP in effector T cells, FOXO1-GFP/fl mice were crossed to mice expressing the Cre recombinase under the control of the granzyme B promoter sequence [Supplementary Figure 5B and (33, 34)] generating FOXO1-GFP/fl GzmB cre mice.

Female FOXO1-GFP/fl GzmB cre+ mice and control GzmB cre+ mice aged between 11 and 27 weeks were used for RNA sequencing of CTL cultured for 24 h in the presence or absence of inhibitor. In some experiments FOXO1-GFP/fl GzmB cre– mice were used as controls. Experimental mice were age and sex matched. Mice were bred and maintained in the Biological Resource Unit at the University of Dundee using procedures that were approved by the University Ethical Review Committee and under the authorisation of the UK Home Office Animals (Scientific Procedures) Act 1986.

#### Cell Cultures

All cells were activated and cultured in complete RPMI 1640 media containing glutamine (Thermo Fisher Scientific/Gibco), supplemented with 10% FBS (Gibco), penicillin/streptomycin (Gibco) and 50 µM β-mercaptoethanol (Sigma). All cells were cultured at 37°C with 5% CO₂.

For ex vivo naïve CD8⁺ T cells, 24 h TCR activated and 24 h TCR activated in the presence of the PI3K p110δ inhibitor IC87114 (10 µM synthesized in-house), three mice were used per biological replicate. Cells from the three mice were pooled and then equally divided into the three conditions. Three biological replicates were generated per condition. Single cell suspensions were generated by mashing lymph nodes in RPMI media and filtered through a 70 µm cell strainer. For 24 h TCR activated CD8⁺ T cells, they were suspended in complete RPMI media with 100 ng/ml antigenic peptide [glycoprotein amino acids 33–41 (gp33–41)], 20 ng/ml interleukin-2 (IL-2; Proleukin, Novartis) and 2 ng/ml interleukin-12 (IL-12; PeproTech). Where indicated, cells were treated with 10 µM IC87114 inhibitor. DMSO was used as vehicle control. After 24 h, cells were harvested by centrifugation and prepared for cell sorting to isolate pure CD8⁺ T cell populations.

To generate CTL from P14 transgenic mice, lymph nodes or spleens from three mice were used to generate three biological replicates. Lymph nodes were homogenised as described above. Spleens were mashed in red blood cell lysis buffer (150 mM NH₄Cl, 10 mM KHCO₃, 110 µM Na₂EDTA pH 7.8), filtered through a 70 µm cell strainer and then suspended in complete RPMI media supplemented with 100 ng/ml gp33–41 peptide, 20 ng/ml IL-2 and 2 ng/ml IL-12 in 10 ml complete RPMI.
Cells were activated for 48 h, then washed out and cultured for a further five days in complete RPMI media supplemented with 20 ng/ml IL-2. Cells were maintained at a cell density of 0.3 × 10^6 live cells/ml.

For transcriptomic and proteomic studies and western blotting of TCR stimulated CTL: on day seven CTL were plated at a cell density of 1 × 10^6 live cells/ml in complete RPMI media supplemented with 20 ng/ml IL-2 and left to rest at 37°C with 5% CO₂ for 1 h. CTL were then stimulated by adding 100 ng/ml gp33–41 peptide directly to the supplemented media for 4 h in the presence or absence of IC87114 inhibitor (10 µM), or MEK inhibitor PD184252 (2 µM, Division of Signal Transduction Therapy (DSTT) Dundee). DMSO was used as vehicle control. Cells were harvested, washed twice with HBSS (Thermo Fisher Scientific/Gibco), snap frozen in liquid nitrogen and stored at −80°C until further processing.

For secretomic studies of TCR stimulated CTL: on day seven CTL were plated at a density of 1 × 10^6 live cells/ml in serum free RPMI media (phenol red free, Thermo Fisher Scientific Gibco) supplemented with 50 µM β-mercaptoethanol (Sigma), Insulin-Transferrin-Selenium 100× (ITS, Gibco) and 20 ng/ml IL-2 and left to rest at 37°C with 5% CO₂ for 1 h. CTL were then stimulated as described above for 4 h in the presence or absence of 10 µM IC87114 inhibitor or 2 µM PD184252 inhibitor or 1 µM AKT inhibitor 1/2 (Merck chemicals). DMSO was used as vehicle control. Supernatants were then collected, passed through a 0.22 µm filter, snap frozen in liquid nitrogen and stored at −80°C until further processing.

For ELISA: CTL were plated at a density of 1 × 10^6 live cells/ml in complete RPMI media supplemented with 20 ng/ml IL-2 and left to rest at 37°C with 5% CO₂ for 1 h prior stimulation with 100 ng/ml gp33–41 peptide added to the supplemented media for 4 h in the presence or absence of 10 µM IC87114 inhibitor or 2 µM PD184252 inhibitor or 1 µM AKT inhibitor 1/2. DMSO was used as vehicle control. Supernatants were then collected, snap frozen in liquid nitrogen and stored at −80°C until further processing.

To generate CTL from FOXO1-GFPfl/fl GzmB cre+ mice (FOXO1-GFP KO) and control GzmB cre+ mice (WT), lymph nodes or spleens were used and single cell suspensions were prepared as described above. Cells were activated with 0.5 µg/ml anti-mouse CD3 (clone 145-2C11 Biolegend), 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells were activated for 48 h, then washed out and cultured in complete RPMI media supplemented with 20 ng/ml IL-2. On days six or seven, cells were plated at a density of 1 × 10^6 live cells/ml in the presence or absence of IC87114 inhibitor for 1 h (10 µM). DMSO was used as vehicle control.

**Cell Sorting**

Cell sorting was performed on a Sony SH800S cell sorter (Sony Biotechnology). Staining was performed in PBS supplemented with 1% FBS. Sorting and cells collection for ex vivo naïve CD8⁺ T cells and 24 h TCR activated CD8⁺ T cell with or without inhibitor was performed in RPMI 1640 containing glutamine, supplemented with 1% FBS. Sorting and cell collection for FOXO1-GFP KO and WT CTL was performed in RPMI 1640 containing glutamine, supplemented with 10% FBS.

Fluorophore-conjugated antibodies were obtained from BD Biosciences, eBioscience or Biolegend.

- For transcriptome in T Cells

To generate CTL from FOXO1-GFPfl/fl GzmB cre+ mice (FOXO1-GFP KO) and control GzmB cre+ mice (WT), lymph nodes or spleens were used and single cell suspensions were prepared as described above. Cells were activated with 0.5 µg/ml anti-mouse CD3 (clone 145-2C11 Biolegend), 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells were activated for 48 h, then washed out and cultured in complete RPMI media supplemented with 20 ng/ml IL-2. On days six or seven, cells were plated at a density of 1 × 10^6 live cells/ml in the presence or absence of IC87114 inhibitor for 1 h (10 µM). DMSO was used as vehicle control.

**Forward/Side Scatter**

Forward and side scatter profiles for sorted WT CTL treated or untreated for 24 h with the PI3K p110β inhibitor were acquired on a FACSVerse using FACSuite software and data were analysed using FlowJo software version 10.6.1 (Treestar).

**Flow Cytometry Analysis of Nuclear Extract for FOXO1-GFP Localisation**

Harvested cells were washed in PBS supplemented with 1% FBS and then either not lysed or lysed in 300 µl ice-cold nuclear extraction buffer (3.8 mM trisodium citrate, 9.6 mM NaCl, 0.05% protein) were generated. Cells from WT mice (expressing untagged FOXO1 protein) were used as negative control for GFP expression. Spleens were used and single cell suspensions were prepared as described above. Cells were activated with 0.5 µg/ml anti-mouse CD3, 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells were activated for 48 h, then washed out and cultured in complete RPMI media supplemented with 20 ng/ml IL-2. On days six or seven, cells were plated at a density of 1 × 10^6 live cells/ml in the presence or absence of IC87114 inhibitor for 1 h (10 µM). DMSO was used as vehicle control.

**Cell Sorting**

Cell sorting was performed on a Sony SH800S cell sorter (Sony Biotechnology). Staining was performed in PBS supplemented with 1% FBS. Sorting and cells collection for ex vivo naïve CD8⁺ T cells and 24 h TCR activated CD8⁺ T cell with or without inhibitor was performed in RPMI 1640 containing glutamine, supplemented with 1% FBS. Sorting and cell collection for FOXO1-GFP KO and WT CTL was performed in RPMI 1640 containing glutamine, supplemented with 10% FBS.

Fluorophore-conjugated antibodies were obtained from BD Biosciences, eBioscience or Biolegend.

- For transcriptome in T Cells

To generate CTL from FOXO1-GFPfl/fl GzmB cre+ mice (FOXO1-GFP KO) and control GzmB cre+ mice (WT), lymph nodes or spleens were used and single cell suspensions were prepared as described above. Cells were activated with 0.5 µg/ml anti-mouse CD3 (clone 145-2C11 Biolegend), 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells were activated for 48 h, then washed out and cultured in complete RPMI media supplemented with 20 ng/ml IL-2. On days six or seven, cells were plated at a density of 1 × 10^6 live cells/ml in the presence or absence of IC87114 inhibitor for 1 h (10 µM). DMSO was used as vehicle control.

**Forward/Side Scatter**

Forward and side scatter profiles for sorted WT CTL treated or untreated for 24 h with the PI3K p110β inhibitor were acquired on a FACSVerse using FACSuite software and data were analysed using FlowJo software version 10.6.1 (Treestar).

**Flow Cytometry Analysis of Nuclear Extract for FOXO1-GFP Localisation**

Harvested cells were washed in PBS supplemented with 1% FBS and then either not lysed or lysed in 300 µl ice-cold nuclear extraction buffer (3.8 mM trisodium citrate, 9.6 mM NaCl, 0.05% protein) were generated. Cells from WT mice (expressing untagged FOXO1 protein) were used as negative control for GFP expression. Spleens were used and single cell suspensions were prepared as described above. Cells were activated with 0.5 µg/ml anti-mouse CD3, 0.5 µg/ml anti-mouse CD28, in 10 ml complete RPMI media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells were activated for 48 h, then washed out and cultured in complete RPMI media supplemented with 20 ng/ml IL-2. On days six or seven, cells were plated at a density of 1 × 10^6 live cells/ml in the presence or absence of IC87114 inhibitor for 1 h (10 µM). DMSO was used as vehicle control.
NP-40). Total cells (used as control to show that PI3K p110δ inhibition increases FOXO1 nuclear localisation but not the total level of FOXO1 protein) and the nuclei of lysed cells were then fixed immediately with 300 µl ice-cold IC fixation buffer (eBioscience) for 15 min at 4°C. After washing, nuclei were stained with DAPI. Samples were acquired on Novocye (Acea Biosciences Inc.) using Novo Express software. Data analysis was performed using FlowJo software version 10.6.1 (Treestar).

ELISA
ELISA kits for GZMB, IFNγ and TNFα (Invitrogen) were used according to the manufacturer’s instructions to determine the effects of 4 h TCR stimulation and PI3K p110δ, MEK or AKT inhibitor treatments on the secretion of these proteins. Experiments were performed in biological triplicate. Statistical analysis was performed with Prism 7 for Mac OS X using unpaired, unequal variance t-test with Welch’s correction. The P values are considered as follow: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ‘ns’ not statistically significant.

Western Blotting
Cell pellets were lysed in RIPA buffer (100 mM HEPES, pH 7.4, 150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM TCEP, and protease and phosphatase inhibitors (Roche)). Cell lysates were sonicated and then centrifuged at 4°C for 13,000 rpm for 10 min.

LDS sample buffer (1×) (Life Technologies) and tris(2-carboxyethyl)phosphine (TCEP, 25mM) was added to the samples prior to incubation at 100°C for 10 min. Samples were loaded and separated by SDS-PAGE (NuPAGE precast gels, Life Technologies), and then transferred to nitrocellulose membranes (Whatman). Blots were probed with the following antibodies: AKT p-S473 (Cell Signalling and Technology, #4058), AKT p-T308 (Cell Signalling and Technology, #4056), AKT (Cell Signalling Technology, #9272), SMC1 (Bethyl Laboratories, A300-055A), p44/42 MAPK p-T202/Y204, Cell Signalling and Technology, #9106) and p44/42 MAPK (Cell Signalling and Technology, #9102). Horseradish peroxidase (HRP)-conjugated secondary antibodies were used (Thermo Scientific). Chemiluminescence was measured using an Odyssey Fc Imaging System (Licor). Image Studio Software (LI-COR) was used to quantify chemiluminescence detected using the Odyssey system. Total protein bands were normalised to the corresponding SMC1 loading control, and then phosphorylated protein bands were normalised to the total protein band and normalised to a control sample (+TCR 4 h). Statistical analysis was performed with Prism 7 for Mac OS X using unpaired, unequal variance t-test with Welch’s correction. The P values are considered as follow: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ‘ns’ not statistically significant.

RNA Extraction for RNA-Sequencing (RNAseq)
Total RNA was extracted from frozen cell pellets of sorted naïve CD8+ T cells and TCR activated with or without inhibitor, CTL either not TCR stimulated or TCR stimulated for 4 h in the presence or absence of inhibitor, and WT or FOXO1-GFP KO CTL with or without 24 h inhibitor treatment using Qiagen RNAeasy mini kit (Qiagen) as per manufacturer’s instructions. Total RNA was quantified using a Nanodrop ND-1000 spectrophotometer. Three biological replicates were generated for each condition.

For naïve CD8+ T cells less than 1 µg of total RNA was supplied; for TCR activated with or without inhibitor cells and all CTL samples 1 µg of total RNA was supplied to the Finnish Functional Genomics Centre of Turku Biosciences whom prepared the libraries and performed the sequencing.

RNA Libraries Preparation and HiSeq Sequencing Run Information
The quality of the total RNA samples was inspected using Agilent Bioanalyzer 2100 or Advanced Analytical Fragment Analyzer and the concentration of the samples was measured with Nanodrop ND-2000 (Thermo Scientific) or Qubit Fluorometric Quantitation (Life Technologies). Libraries preparation was started from 300 ng of total RNA using the Illumina TruSeq Stranded mRNA sample preparation kit (15031047) as per manufacturer’s instructions. Data presented here were run as three independent experiments as follows: one lane for naïve/TCR 24 h activated cells with or without inhibitor (naïve/TCR activated 24 h ± inhibitor) (this lane included also an unpublished dataset not part of this manuscript); one lane for CTL unstimulated or TCR 4 h stimulated with or without inhibitors (Unstim/TCR stimulated 4 h CTL ± inhibitors); and one lane for WT and FOXO1-GFP KO CTL with or without inhibitor for 24 h (WT/FOXO1-GFP KO CTL ± inhibitor 24 h).

The quality of the libraries was confirmed with Advanced Analytical Fragment Analyzer and the concentrations of the libraries were quantified with Qubit Fluorometric Quantitation (Life Technologies). Libraries were sequenced using Illumina HiSeq 3000 (naïve/TCR activated ± inhibitor) or Illumina HiSeq 2500 (TCR stimulated CTL ± inhibitors) or Illumina HiSeq 3000 (WT/FOXO1-GFP KO CTL ± inhibitor) instruments using paired-end sequencing chemistry and 75 bp (naïve/TCR activated ± inhibitor) or 100 bp (TCR stimulated CTL ± inhibitors) or 75 bp (WT/FOXO1-GFP KO CTL ± inhibitor) read length. The typical yields are 120–150 × 10^6 paired-end reads per lane on Illumina HiSeq 2500 and 260–310 × 10^6 paired-end reads per lane on Illumina HiSeq 3000.

RNAseq Data Processing
Naïve/TCR activated ± inhibitor and TCR stimulated CTL ± inhibitors: raw reads were first aligned against the *Mus musculus* mm10 reference genome using the STAR aligner (34) (versions 2.5.2b or 2.4.2a) and then associated with known genes using the RefSeq annotation. The number of reads associated with each gene was counted using subreads package (versions 1.5.1 and 1.5.0). Genome (*Mus musculus* mm10) and reference gene annotations (RefSeq based annotation) were downloaded from Illumina iGenomes web site.

WT/FOXO1-GFP KO CTL ± inhibitor: read quality was evaluated and confirmed using MultiQC (35). Raw reads were
aligned to the GRCm38.p6 (Ensembl) build of the Mus musculus reference genome using the STAR aligner (34) (version 2.7.1a), with 'outFilterType BySjOut' option to reduce the number of spurious junctions. The STAR quantMode GeneCounts option was used to map aligned reads to genes to generate a gene counts matrix, using the annotation file GRCm38.98 (Ensembl).

For all experiments, the noise from low count genes was reduced using the filterByExpr function. The resulting count matrix was normalised by the Trimmed Mean of M-values (TMM) method using the edgeR package (36, 37). EdgeR RPKM function was used on TMM-normalised counts to calculate FPKM values, with total exon length calculated using GenomicRanges (38) as the sum of the non-overlapping exonic regions for a gene.

Differential expression analysis was performed using Limma package (39). Reads were converted to log, counts per million and precision weighted using the voom function. A linear model was fitted to each gene and empirical Bayes moderated t-statistics were applied. P values were adjusted to control the global false-discovery rate.

All scripts used to perform analysis are available from authors upon request.

**Statistics and Calculations RNAseq Data**

Genes were defined as differentially expressed if they had an adj. P value <0.05 and a fold change >2 or <0.5 (Naïve/TCR activated ± inhibitor and TCR stimulated CTL +/- inhibitors); and a fold change >1.5 or <0.67 (WT/FOXO1-GFP KO ± inhibitor). *adj. P <0.05 and fold change >2 or <0.5 and fold change >1.5 or <0.67.

For the gene ontology (GO) Term enrichment analysis, GO terms enriched in the statistically significant changed gene were identified using the functional annotation tools within DAVID Bioinformatics Resources 6.8, NIAID/NIH (http://david.ncifcrf.gov). The top 5 GO terms describing "biological process" annotation were identified based on P value and terms represented by <3 genes in the changed gene list were excluded from the analysis.

Heatmaps were generated using the Morpheus tool from the Broad Institute (http://software.broadinstitute.org/morpheus). Heatmap in Figure 2B was arranged with IFNγ positioned at the top and with all mRNA ranked according to similarity using the nearest-neighbor analysis and Pearson correlation. Heatmap in Figure 2D was arranged with Aacs positioned at the top. The other heatmaps, with the exclusion of heatmaps in Figures 6F, G, were arranged with the indicated mRNA on the top and the others ranked according to similarity using the nearest-neighbor analysis and Pearson correlation. Heatmaps in Figures 6F, G were arranged following the order of Figures 3G, H.

Venn diagrams were generated using Venny 2.1 from BioinfoGP (http://bioinfogp.cnb.csic.es/tools/venny) (40).

**Proteomics Sample Preparation**

Cell pellets were lysed in 0.5 ml urea lysis buffer (8 M urea, 100 mM Tris pH 8.0, protease (cOmmplete Mini EDTA-free, Roche) and phosphatase inhibitors (PhosSTOP, Roche) and vigorously mixed for 30 min at room temperature. Samples were sonicated with a Branson digital sonicator and protein concentration was determined by BCA assay as per manufacturer’s instructions (Thermo Fisher Scientific). Lysates were reduced with 10 mM dithiothreitol (DTT) and incubated at 30°C for 30 min before being alkylated with 50 mM iodoacetamide (IAA) in the dark at room temperature for 45 min. Lysates were then diluted with tris buffer (100 mM tris pH 8.0, 1 mM CaCl₂) to 4 M urea. LysC (Wako), reconstituted in tris buffer, was added to the samples at a 50:1 (protein:LysC) ratio and incubated at 30°C overnight. Samples were then transferred to low-bind 15 ml Falcon tubes (Eppendorf) and further diluted with tris buffer to 0.8 M urea before trypsin (Promega), reconstituted with tris buffer, was added at a ratio of 50:1 protein/trypsin and incubated at 30°C for 8 h. After digestion, samples were adjusted to 1% trifluoroacetic acid (TFA) prior desalting with C18 Sep-Pack cartridges (Waters). The cartridges were washed twice with 1 ml elution buffer (50% acetonitrile ACN/0.1%TFA) and equilibrated twice with 1 ml wash buffer (0.1% TFA). Acidified peptides were loaded twice and then washed three times with 1 ml washing buffer. Peptides were eluted into Eppendorf Protein LoBind tubes by 2 elutions of 600 μl elution buffer each and dried down in a SpeedVac (Genevac).

**Strong Anion Exchange Chromatography**

Dried peptide samples were resuspended in 210 μl SAX sample buffer (10 mM sodium borate–20% (v/v) acetonitrile), pH was adjusted to pH 9.3 with 1 M NaOH if necessary, and then fractionated with an UltiMate 3000 HPLC (high-performance liquid chromatography) system equipped with an AS24 SAX column. For the separation, the buffers used were 10 mM sodium borate (pH 9.3) (SAX buffer A) and 10 mM sodium borate (pH 9.3), 500 mM NaCl (SAX buffer B). An exponential elution gradient starting with Buffer A was used to separate the peptides into 16 fractions, which were collected and desalted with Sep-Pack C18 96-well desalting plates (Waters). Desalted peptides were then dried down with a SpeedVac (Genevac). Dried fractions were then resuspended in 1% formic acid, and separated by nanoscale C18 reverse-phase chromatography (UltiMate 3000 RSLCnano System, Thermo Fisher Scientific) before being electrospayed into the linear trap quadrupole–Orbitrap mass spectrometer (LTQ Orbitrap Velos Pro; Thermo Fisher Scientific) as described previously (22). The chromatography buffers used were as follows: HPLC buffer A (0.1% formic acid), HPLC buffer B (80% acetonitrile and 0.08% formic acid), and HPLC buffer C (0.1% formic acid). Peptides were then loaded onto an Acclaim PepMap100 nanoViper C18 trap column (100 μm inner diameter, 2 cm; Thermo Fisher Scientific) in HPLC buffer C with a constant flow of 5 μl/min. After trap enrichment, peptides were eluted onto an EASY-Spray PepMap RSLC nanoViper, C18, 2 μm, 100 Å column (75 μm, 50 cm; Thermo Fisher Scientific) using the following buffer gradient: 2% B (0 to 3 min), 2 to 40% B (3 to 128 min), 40 to 98% B (128 to 130 min), 98% B (130 to 150 min), 98% C (150 to 151 min), 98% C (80% acetonitrile) and 0.08% formic acid, and eluted in 0.3 μl/min. The eluting peptide solution was automatically electrospayed into the coupled linear trap quadrupole–Orbitrap mass spectrometer (LTQ Orbitrap Velos Pro; Thermo Fisher Scientific) using an EASY-Spray nanoelectrospray ion source at 50°C and a source voltage of 1.9 kV (Thermo Fisher Scientific). The mass spectrometer was operated in positive ion mode. Full-scan MS survey spectra
Peptide intensity and the summed peptide intensities of the other histones present in a sample. The ratio between the histone mouse cell get assigned to the summed peptide intensities of all for all identi

The data set

Wisniewski et al. (42). Copy numbers of histones in a diploid calculated using the proteomic ruler plugin as described in

residues was set as a

used for data

were selected as the proteolytic enzymes; up to two missed cleavages were permitted; protein and PSM False discovery

variable modi

and glutamine and asparagine deamidation were selected as

The following search parameters were used: protein N-terminal acetylation, methionine oxidation, glutamine to pyroglutamate,

dependent acquisition (DDA): the 15 most intense peptide

The lock mass option was enabled for survey scans to improve mass accuracy. MS was performed by the Proteomics Facility, University of Dundee, UK.

Processing and Analysis of Proteomic Data

The data were processed, searched and quantified with the MaxQuant software package (version 1.6.10.43). Proteins and peptides were identified using a hybrid database from databases in Uniprot release 2020 06 as described in Marchingo et al. (41).

The following search parameters were used: protein N-terminal acetylation, methionine oxidation, glutamine to pyroglutamate, and glutamine and asparagine deamidation were selected as variable modifications; carbamidomethylation of cysteine residues was set as a fixed modification; Trypsin and LysC were selected as the proteolytic enzymes; up to two missed cleavages were permitted; protein and PSM False discovery rates was set to 0.01 and matching of peptides between runs was switched off. Perseus software package (version 1.6.6.0) was used for data filtering and protein copy number quantification. Proteins were quantified from unique (found only in a specific protein group) and razor (peptides assigned to a specific protein group without being unique to that group) peptides. The data set was filtered to remove proteins categorised as "contaminants", "reverse" and "only identified by site". Copy numbers were calculated using the proteomic ruler plugin as described in Wisniewski et al. (42). Copy numbers of histones in a diploid mouse cell get assigned to the summed peptide intensities of all histones present in a sample. The ratio between the histone peptide intensity and the summed peptide intensities of the other identified proteins is then used to estimate copy number per cell for all identified proteins in the data set.

Statistics and Calculations Proteomic Data

Three biological replicates were generated. P values were calculated via a two-tailed, unequal-variance t-test on log10 transformed copy number per cell values in Microsoft Excel. P values <0.05 were considered as being statistically significant. Fold change >2 or <0.5 were considered as cut-off. Heatmaps were generated using the Morpheus tool from the Broad Institute (http://software.broadinstitute.org/morpheus). *P <0.05 and fold change >2 or <0.5.

Secretomics Sample Preparation

For this experiment, 400 μl of supernatant was used for each sample and peptides were generated using the S-Trap mini column method (Protifi). Briefly, samples were mixed on a shaker at 1,000 rpm at room temperature for 5 min after addition of 10 mM TCEP and 50 mM TEAB (Triethylammonium bicarbonate) and then transferred to a ThermoMixer shaking at 500 rpm at 95°C for 5 min before being mixed again at 1,000 rpm at room temperature for 5 min. Samples were alkylated with 20 mM Iodoacetamide (IAA) in the dark at room temperature for 1 h and protein concentration was determined using the EZQ method (Thermo Fisher Scientific) according to the manufacturer’s instructions. Lysates were acidified by addition of 1.2% phosphoric acid and then mixed by vortexing. S-Trap binding buffer (90% methanol and 100 mM TEAB pH 7.1) was added at a 1:7 ratio of lysate to S-Trap binding buffer, loaded on S-Trap mini columns (Protifi) and then centrifuged at 6,500 rpm for 30 s. Bound protein was washed five times by addition of 400 μl of S-Trap binding buffer and centrifugation at 6,500 rpm for 30 s. Digestion buffer (125 μl) containing trypsin in a ratio protein 1:trypsin 20 was added into the top of the column and incubated at 47°C for 2 h without shaking. Peptides were then eluted by addition and centrifugation of 80 μl of digestion buffer, 80 μl of 0.2% aqueous formic acid and 80 μl of 50% aqueous acetonitrile containing 0.2% formic acid. Eluted peptides were dried down in a SpeedVac (Genevac) and then reconstituted in 5% formic acid by shaking at 1,000 rpm at 30°C for 1 h. Peptides were run on a Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) as single shot in a data-dependent acquisition (DDA) mode (120 min). MS was performed by the Proteomics Facility, University of Dundee, UK. The data were processed, searched and quantified as described above with only trypsin selected as proteolytic enzyme. Raw intensity for each replicate was normalised to the corresponding control and expressed as % intensity relative to TCR. Statistical analysis was performed with Prism 7 for Mac OS X using unpaired, unequal variance t-test with Welch’s correction. The P values are considered as follow: *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001.

RESULTS

PI3K p110δ Control of Antigen Receptor Transcriptional Programs in Naïve CD8+ T Cells

TCR driven activation of naïve T cells is the key step in directing the differentiation of effector T cells. Therefore, to understand how PI3K p110δ controls CD8+ T cell differentiation we first assessed the contribution of PI3K p110δ signalling pathways to the transcriptional remodelling initiated by the TCR. The cell model used was P14 CD8+ T cells expressing a TCR specific for lymphocytic choriomeningitis virus (LCMV) glycoprotein peptide gp33–41. To define the PI3K p110δ transcriptional programs we used RNA sequencing to examine the transcriptome of naïve CD8+ T cells before and after 24 h of activation with the LCMV glycoprotein peptide gp33–41 in the presence or absence of the selective PI3K p110δ inhibitor IC87114 (PI3Kdi). In these experiments we quantified 11,262 mRNA and using a fold change cut off >2 fold and adj. P value <0.05 we saw that the abundance of 5,613 mRNA was modified by antigen receptor engagement (Figure 1A; Supplementary Table 1 and Supplementary Datasheet 1). There are a number of mRNA (2,722), which represent around 24% of the total transcriptome measured, that are expressed in naïve T cells and
downregulated upon immune activation including mRNA encoding transcription factors which maintain pluripotency and cell quiescence (e.g. Klf2 and Tcf7), translational repressors such as Pdcd4 and growth factor receptors such as Il7 and Il6 receptors (Supplementary Table 1).

There are also a large number of mRNA (2,891), around 26% of the total transcriptome measured, whose abundance increases following immune activation and this includes mRNA encoding proteins annotated in a GO term enrichment analysis as cell cycle machinery and ribosomal biogenesis (Figure 1B and Supplementary Table 1) but also includes nutrient transporters (Figure 1C), transcription factors (Figure 1D) and a wide array of cytokines, growth factors and chemokines (Figure 1E).

What are the consequences of inhibiting PI3K p110δ during TCR activation on the CD8⁺ T cell transcriptome? Overall, PI3K p110δ inhibition controlled the expression of 670 mRNA (>2 fold change threshold and an adj. P value of <0.05) in the TCR activated CD8⁺ T cells (Figure 2A), which represent 6% of the total 11,262 mRNA identified. There are 257 mRNA whose expression is repressed and more than 400 mRNA whose expression is increased by loss of PI3K p110δ activity (Supplementary Table 2 and Supplementary Datasheet 1). The selectivity of the effects of PI3K p110δ inhibition is striking as shown by Figure 2B which uses nearest neighbor analysis and Pearson correlation to group and align the expression profile of 11,262 mRNA in naïve, TCR activated CD8⁺ T cells and CD8⁺ T cells activated via their TCR in the presence of the PI3K p110δ inhibitor. These data show that a large portion of the TCR regulated transcriptional programs is PI3K p110δ independent. Of note, PI3K p110δ does not mediate TCR induced changes in the abundance of transcripts encoding the metabolic machinery that mediate glycolysis, one carbon or fatty acid metabolism (Figures 2C, D and Supplementary Figure 1A). Moreover,
TCR engagement switches on expression of the transcription factors Myc and Hif1 alpha (Hif1α), which control expression of amino acid transporters and glucose transporters (41, 43, 44) respectively, even in the absence of PI3K p110δ activity (Figure 2E). Indeed expression of Hif1α mRNA was increased relative to controls in cells activated in the absence of PI3K p110δ activity. The selectivity of the effects of PI3K p110δ signalling is also highlighted by exploring the impact on the expression of mRNA encoding key transcription factors that control CD8+ T cell differentiation: over 300 transcription factors were identified using the annotation DNA binding/transcription factor activity (GO:0003700) and only 31 are controlled by PI3K p110δ (Figure 2F and Supplementary Datasheet 1). As examples, the ability of the TCR to downregulate expression of Klf2 and Tcf7 is...
not PI3K p110δ dependent. Nor does PI3K p110δ inhibition prevent TCR induction of Tbx21, Blimp1 and Irf4, key drivers of CD8+ T cell differentiation (Figure 2F and Supplementary Figure 2A). Nevertheless, there are some key CD8+ T cell transcription factors whose expression is PI3K p110δ dependent including Eomes (Figure 2F and Supplementary Figure 2A). There are also increases in expression of mRNA encoding the transcriptional repressors BACH2 and ID2 in PI3K p110δ inhibitor treated cells (Figure 2F and Supplementary Figure 2A).

What are the PI3K p110δ controlled processes in T cells? Here GO term enrichment analysis reveals the dominant effect of PI3-kinase signalling pathways in TCR activated cells is to control expression of transcripts annotated as ‘immune response molecules’ (Figure 2G). For example, TCR triggering induces an increase in expression of mRNA encoding the important T cell costimulatory molecules 4-1BB, CD28 and ICOS: TCR mediated upregulation of mRNA encoding 4-1BB is dependent on PI3K p110δ; whereas Icos and Cd28 mRNA is increased in PI3K p110δ inhibitor treated cells (Figure 2H).

Antigen activation also causes T cell to switch on expression of mRNA encoding a diverse array of cytokines, chemokines and cytotoxic effector molecules. These include Interleukin-2 (IL-2), Interferon gamma (IFNγ), Tumour necrosis factor (TNF), Interleukin-3 (IL-3), Interleukin-24 (IL-24), Lymphotoxin-alpha (LTα), Leukemia inhibitory factor (LIF), CD40 ligand (CD40lg), Chemokine (C-C motif) ligand 3 (CCL3), Chemokine (C-C motif) ligand 4 (CCL4), Chemokine (C motif) ligand 1 (XCL1). The induction of this subset of mRNA is all dependent on activation of PI3K p110δ (Figure 2I). The expression of mRNA encoding effector CD8+ T cell cytolytic molecules like granzymes and perforin also depends on PI3K p110δ activity in TCR activated CD8+ T cells (Figure 2J).

PI3K p110δ activation thus both positively and negatively controls the expression of T cell costimulatory molecules and is required for the production of multiple cytokines and effector molecules that allow CD8+ T cells to mediate adaptive immune responses. It is particularly striking that PI3K p110δ activity is required for the production of CCL3, CCL4 and XCL1 as these are the essential chemokines used by immune activated CD8+ T cells to direct their interactions with dendritic cells/macrophages (45, 46).

PI3K p110δ Control of Transcriptional Programs in Effector Cytotoxic CD8+ T Cells

The TCR-PI3K p110δ signalosome is remodelled during T cell differentiation (47) but the contribution of PI3K p110δ to TCR triggered transcriptional programs in effector CD8+ T cells has not been assessed. To address this question, antigen-primed P14 TCR transgenic CD8+ T cells were clonally expanded in IL-2 to produce differentiated CTL. RNA sequencing then compared the transcriptome of CTL before and after retriggering of the TCR with the LCMV glycoprotein peptide gp33–41 in the presence or absence of the PI3K p110δ inhibitor IC87114. The data show that out of 11,022 mRNA, TCR triggering induces increased expression of 1,039 mRNA and downregulated expression of 1,294 mRNA (fold change >2 and an adj. P value <0.05), representing just over 20% of the total transcriptome measured (Figure 3A; Supplementary Table 3 and Supplementary Datasheet 2). The upregulated mRNA in TCR activated CTL encode cytokines, growth factors and chemokines highlighting how one key role of antigen receptor triggering in effector T cells is to produce molecules that communicate pathogen recognition to other cells of the immune system (Figures 3B, C). The downregulated mRNA in TCR activated CTL encode genes annotated in a GO term enrichment analysis as “cell cycle” (Figure 3D) that includes E2F transcription factors (E2f1–E2f2–E2f7–E2f8), cyclin A2 (Ccna2), cyclin B2 (Ccnb2) and cyclin D3 (Ccn3) (Supplementary Figures 3A, B).

As in the naïve T cells, only a small fraction (less than 3%) of the TCR induced transcriptional programs is sensitive to inhibition of PI3K p110δ in CTL. Blocking PI3K p110δ activity decreased expression of approximately 185 mRNA and increased the abundance of 78 mRNA (Figure 3E, Supplementary Table 4 and Supplementary Datasheet 2). Enrichment analysis of the downregulated mRNA revealed that the top 3 enriched GO...
terms for PI3K p110δ sensitive processes are biological processes involving cytokines and chemokines (Figures 3F–H). Figure 3G thus shows that PI3K p110δ activity is required for the production of mRNA encoding multiple cytokines including Granulocyte–macrophage colony-stimulating factor (GM-CSF/CSF2), IL-2, TNF, IL-3, IL-24, IL-10, Ltα, CD40lg. Notably, PI3K p110δ activity is also required for the TCR induced production of chemokine mRNA including CCL9 and XCL1 (Figure 3H).

Moreover, the effects of PI3K p110δ inhibition on expression of mRNA encoding chemokines and cytokines were paralleled by changes in the production of cytokine and chemokine proteins as measured by high resolution mass spectrometry analysis of the proteomes and secretomes of unstimulated or P14 CTL activated with cognate peptide for 4 h in the presence or absence of the PI3K p110δ inhibitor (Figure 3I and Supplementary Datasheet 4).

FIGURE 3 | Continued
In TCR activated naïve T cells, PI3K p110δ activity directed expression of the cytolytic effector molecules granzyme B and perforin (Figure 2J). mRNA and protein levels for these effector molecules are already high in CTL (Figure 3I) [Supplementary Figure 4A and (48)]. However, neither granzyme nor perforin expression is PI3K p110δ regulated in CTL (Figure 3I). Here, an important consideration is that a primary function of TCR engagement in CTL is to induce degradation of cytolytic effector molecules. TCR activated CTL thus lose intracellular granzyme B protein following TCR engagement (Figure 3K). This response is not prevented by PI3K p110δ inhibition, with the same amount of granzyme B content remaining in the cell in CTL after 4 h retriggering with or without inhibitor (Figure 3K). Analysis of granzyme B levels in cell supernatants also failed to see an impact of PI3K p110δ inhibition on granzyme B exocytosis (Figure 3L). PI3K p110δ thus does not control the TCR mediated production of cytolytic T cell granules or degranulation processes in CTL.

The Impact of Sustained Loss of PI3K p110δ Activity on CTL Transcriptional Programs

In these initial CTL experiments we examined the impact of PI3K p110δ inhibition on an immediate (4 h) response of CTL to TCR engagement. The rationale for this time point was that CTL activated via the TCR undergo activation induced cell death making it difficult to interpret data from longer time points. However, to explore further how PI3K p110δ controls CTL biology, we also examined the impact of sustained inhibition of PI3K p110δ on CTL phenotypes. In this context, CTL maintained in IL-2 have high levels of PtdIns(3,4,5)P3, produced by sustained activity of PI3K p110δ (6, 7). RNA sequencing was thus used to compare the transcriptome of CTL maintained for 24 h in the presence or absence of the PI3K p110δ inhibitor IC87114. In this setting, blocking PI3K p110δ activity did not affect the growth and death of effector CD8+ T cells [Figures 4A, B and (23)] but did modulate the CTL transcriptome. Figure 4C shows increased expression of 254 mRNA and decreased expression of 96 mRNA in CTL lacking PI3K p110δ activity (Supplementary Table 5 and Supplementary Datasheet 3). The mRNA dependent on sustained PI3K p110δ activity in CTL includes chemokines and cytokines (Figure 4D). Interestingly, there is no PI3K p110δ regulation of mRNA encoding the costimulatory molecules 4-1BB and ICOS (Figure 4E) or mRNA encoding cytolytic effector molecules granzyme and perforin (Figure 4F).

The absence of any effect of PI3K p110δ inhibition on expression of cytolytic effector molecules and 4-1BB and ICOS is a fundamental difference between naïve T cells and CTL (Figures 2H, J and Figures 4E, F). One other difference, in terms of the impact of PI3K p110δ inhibition on TCR responses in naïve T cells versus CTL, is the magnitude of the effects. There are many more TCR regulated transcripts dependent on PI3K p110δ activity in naïve T cells than in CTL (Figure 4G).

What are the PI3K p110δ regulated mRNA in CTL? The GO term annotation for mRNA that increased in expression following loss of PI3K p110δ activity in CTL identified molecules linked to the control of cell adhesion and migration, notably CD62L (Sel) an adhesion molecule that controls T cell trafficking into secondary lymphoid tissue and Ccr7 and sphingosine 1-phosphate receptor 1 (Sipr1), chemokine receptors that regulates lymphocyte entry and egress from lymphoid tissues (Figures 4H, I, and Supplementary Table 5). These have previously been described as proteins whose expression is controlled by PI3K p110δ (29, 49). mRNA that increases in expression in CTL treated with the PI3K p110δ inhibitor also include the interleukin 7 receptor (Ilt7) and the transcription factors Tcf7 and Klf2 (Figure 4I and Supplementary Table 5).

Are there any new insights about the role of PI3K p110δ in effector CD8+ T cells from these experiments? One fundamental observation is that sustained loss of PI3K p110δ activity in CTL...
FIGURE 4  Impact of sustained PI3K p110δ inhibition on CTL transcriptional programs. WT CTL were maintained for 24 h in the presence or absence of the PI3K p110δ inhibitor IC87114 (PI3Kδi) and RNAseq was used to characterise their transcriptome. (A) Forward/side scatter flow cytometry analysis of IL-2/IL-12 maintained or 24 h inhibitor treated WT CTL. (B) Percentage of cell death at the end of the culture quantified by flow cytometry as proportion of cells DAPI positive. (C) Volcano plot showing the ratio for 24 h PI3K p110δ inhibitor (PI3Kdi) treated cells versus untreated WT CTL. mRNA significantly different between the two populations shown in red (fold change >1.5 or <0.67; adj. P values <0.05). The horizontal dashed lines indicate an adj. P value of 0.05 shown as −log10 while vertical dashed lines indicate a fold change of 1.5 and 0.67 shown as log2. The vertical solid line indicates the mean of log2 ratio. (D–F) Histograms showing mRNA expression levels (FPKM) for Ifnγ, Ccl3, Ccl4, Tnfrsf9/4-1BB, Icos, Gzm and Pft1. FPKM shown as the mean of three biological replicates ± standard deviation. (G) Percentage of the impact of PI3K p110δ inhibition on the total transcriptome of TCR activated naïve (left) and effector CD8+ T cells (right). (H) GO term enrichment analysis for biological processes for mRNA whose expression was induced by sustained inhibition of PI3K p110δ activity. The top 5 processes are presented. (I) Heatmap of known FOXO1 targets in WT CTL cultured for 24 h in the presence or absence of PI3K p110δ inhibitor (PI3Kδi): Sell, Il7r, St1p1, Tcf7, Ccr7 and Klf2. The relative mRNA abundance is graded from low (blue) to high (red) per row. Input data for the heatmap are listed in Supplementary Datasheet 3. (J, K) mRNA expression levels (FPKM) of Cctδ4 in (J) WT CTL ± PI3K p110δ inhibitor (PI3Kδi) for 24 h and (K) in TCR stimulated CTL ± PI3K p110δ inhibitor (PI3Kδi) for 4 h. FPKM shown as the mean of three biological replicates ± standard deviation. (L) mRNA expression levels (FPKM) for inhibitory receptors Pdcd1/PD-1, Havor/2/TIM-3, Lag3 and Slam6 in WT CTL ± PI3K p110δ inhibitor (PI3Kδi). (D, J, K, L)* adj. P <0.05 and fold change >1.5 or <0.67.
increases mRNA expression of the important inhibitory receptor Ctla4 (Figure 4J). Increased Ctla4 expression was also seen in TCR activated CTL treated with the PI3K p110δ inhibitor for 4 h (Figure 4K). In this respect other critical inhibitory receptors that control CTL function are PD-1, LAG3, TIM3 and SLAMF6: there is no effect of PI3K p110δ inhibition on the mRNA expression of PD-1 or TIM3 but the mRNA expression of LAG3 and SLAMF6 is induced by loss of PI3K p110δ activity (Figure 4L). These results inform that the activation of PI3K p110δ represses the expression of three important inhibitory receptors: Ctla4, Slamf6 and Lag3 in CTL.

The Contribution of PKB/AKT, FOXO1 and ERK1/2 to the Control of Cytokine and Chemokine Production in CTL

One major role for PI3K p110δ in CTL is to control the nuclear localisation of the transcription factor FOXO1. CTL have high levels of PtdIns(3,4,5)P3, which drives phosphorylation and activation of the serine/threonine kinase AKT which phosphorylates FOXO1 causing its nuclear exclusion. Inhibition of PI3K p110δ, which prevents PtdIns(3,4,5)P3 production and AKT phosphorylation, causes a rapid translocation of FOXO1 to the nucleus [Figure 5A and (6)]. Here, a pertinent point is that the PI3K p110δ repression of CD62L, CCR7, S1PR1, IL7R, TCF7 and KLF2 is mediated by FOXO1 (29, 49). A key question then is whether the repressive effect that PI3K p110δ activity has on the expression of Ctla4, Slamf6 and Lag3 mRNA in CTL is mediated by FOXO1. In this context, it has been described that the expression of PD-1 in CD8+ T cells is FOXO1 mediated (28) but the role of FOXO1 in controlling expression of other inhibitory receptors in CTL has not been examined.

To explore the mechanisms used by PI3K p110δ to control T cells we analysed the impact of PI3K p110δ inhibition on the expression of mRNA encoding CTLA4, SLAMF6, PD-1, TIM-3 and LAG3 in FOXO1 null CTL (FOXO1-GFP KO). To delete Foxo1 in CTL we backcrossed mice with floxed Foxo1-EGFP alleles (32) to transgenic mice expressing Cre recombinase under the control of a granzyme B promoter that allows deletion of FOXO1-GFP in CTL (Figure 5B, Supplementary Figures 5A, B). In normal CTL >90% of FOXO1 is excluded from the nucleus and hence is transcriptionally inactive, whereas in CTL treated with the PI3K p110δ inhibitor FOXO1 relocates to the nucleus. We therefore performed RNA sequencing of FOXO1-GFP null CTL before and after 24 h treatment with the PI3K p110δ inhibitor and compared to WT treated CTL (Supplementary Datasheet 3). The full list of FOXO1 dependent mRNA identified in these experiments is shown in supplemental data (Supplementary Table 6) and includes previously identified FOXO1 targets including Tcf7, Klf2 and S1pr1 and as well as the transcription factor Hif1α (Figure 5C). There were also mRNAs whose expression was enhanced in FOXO1 null CTL (Figure 5C). These data also show that the expression of Ctla4 and Slamf6 mRNA is dependent on FOXO1 (Figure 5D). In this respect, recent chromatin analysis (ChIP-seq) has identified FOXO1 binding to Ctla4 and Slamf6 gene loci and ATAC-seq analytic comparisons of wild type and FOXO1 null CD8+ T cells have indicated reduced chromatin accessibility in the Ctla4 and Slamf6 gene loci in FOXO1 null CD8+ T cells [Supplementary Figure 6A and (50)].

Interestingly, not all inhibitory receptor mRNA expression was changed in FOXO1 null CTL. Figure 5D shows Lag3 mRNA is still expressed in FOXO1 null CTL, though it is marginally lower, and PD-1 and TIM-3 are not regulated by PI3K p110δ or FOXO1 (Figure 5D). It is also pertinent that not all PI3K p110δ regulated mRNA in CTL are sensitive to FOXO1 deletion (Figure 6A; Supplementary Table 7 and Supplementary Datasheet 3). For example, inhibition of PI3K p110δ in CTL causes decreased expression of chemokine (Ccl3, Ccl4) and cytokine (Ifnγ) mRNA in both WT and FOXO1 null T cells (Figure 6B). In this respect, previous studies have shown that the nuclear exclusion of FOXOs is necessary for the production of Interferon gamma (23), which would be consistent with a repressive role for FOXO1 in the control of Interferon gamma production. The current data found no evidence for enhanced expression of Interferon gamma mRNA in FOXO1 null CTL (Figure 6B), which highlights that the regulation of this key cytokine is not controlled by a simple FOXO1 dependent switch but requires coordination with other signalling pathways. It also argues that the profound effect of PI3K p110δ on Interferon gamma production is not mediated solely by PI3K p110δ control of FOXOs. In this respect, CTL lacking PI3K p110δ activity show reduced activation of the MAP kinases ERK1 and ERK2 in response to antigen receptor engagement [Figure 6C, Supplementary Figure 7A and (29, 30)]. This is germane because the activity of ERK1/2 is necessary for cytokine and chemokine production by antigen activated naïve CD8+ T cells (51). We therefore evaluated the PKB/AKT and ERK1/2 signalling requirements of antigen receptor induced cytokine and chemokine production in CTL. The data show that TCR induced production of multiple chemokines and cytokines is dependent on both the activation of the PKB/AKT serine threonine kinases and ERK1/2 activity (Figures 6D, E). In particular the PI3K p110δ controlled cytokines and chemokines mRNA, shown in Figures 3G, H and protein in Figure 3I, are also ERK1/2 controlled (Figures 6F–I, Supplementary Figure 8A, Supplementary Tables 8, 9 and Supplementary Datasheets 2, 4). These data collectively highlight that PI3K p110δ control of the CD8+ T cell transcriptional programs reflects the role of this lipid kinase in coordinating the activity of multiple signalling pathways.

DISCUSSION

The aim of the present study was to gain an in-depth knowledge of the contribution of PI3K p110δ to antigen receptor controlled programs in naïve and effector CD8+ T cells to understand how this lipid kinase controls CD8+ T cell differentiation. One important conclusion is that the dominant targets for PI3K p110δ regulation are the secreted molecules and cell surface receptors that mediate CD8+ T cells communication with other immune cells. The production of multiple cytokines by TCR activated CD8+ T cells thus requires PI3K p110δ activity. Notable amongst these are cytokines that control the activation of monocytes and macrophages such as GM-CSF/CSF2, TNF and IFNγ. One other important insight is that PI3K p110δ controls the production of chemokines mRNA which orchestrate the ability of CD8+ T cells to recruit innate immune cells to sites of infection (45, 52).
PI3K p110δ activity also selectively shapes the repertoire of costimulatory receptor that control CD8+ T cell differentiation. For example, in naïve CD8+ T cells, TCR induced upregulation of the mRNA encoding the costimulatory receptor 4-1BB, which is essential for the persistence of tissue resident CD8+ effector/memory T cells (53–55), is dependent on PI3K p110δ activity.

Further support for the concept that PI3K p110δ controls the ability of CD8+ T cells to communicate with other immune cells includes the role of PI3K p110δ in controlling expression of the inhibitory receptors Cita4 and Slamf6 mRNA in effector CTL. Hence the loss of PI3K p110δ activity and the relocalisation of the transcription factor FOXO1 to the nucleus upregulates Cita4 and Slamf6 mRNA expression. The significance of this result stems from the essential role that CTLA4 and SLAMF6 have as immunomodulatory/inhibitory receptors that restrain peripheral T cell responses to maintain peripheral tolerance (56–58). In this context, an elegant study by Kaech and colleagues has shown that FOXO1 is necessary for the differentiation of PD-1hi Eomes+ terminally exhausted CTL. Moreover, FOXO1 null cytotoxic T cells fail to persist and control chronic viral infection (28). The authors hypothesised that the
FIGURE 6 | Contribution of PI3Kp110δ, FOXO1 and ERK1/2 to the control of cytokine and chemokine production in CTL. (A) Venn diagram showing the overlap in the number of mRNA whose expression was induced by sustained PI3K p110δ inhibition in WT CTL and reduced in treated FOXO1-GFP KO CTL versus WT treated CTL. (B) mRNA expression levels (FPKM) of Ccl4, Ccl3 and Ifnγ in WT and FOXO1-GFP KO CTL ± PI3K p110δ inhibitor. *adj. P <0.05 and fold change >1.5 or <0.67. (C) Quantification of phosphorylated AKT (S473 and T308) and ERK1/2 (T202/Y204) in CTL in response to TCR stimulation in the presence or absence of PI3K p110δ (PI3Kdi) or MEK (MEKi) inhibitor assayed by western blot (Supplementary Figure 7A). (D) Levels of Interferon gamma (IFNg) and Tumour necrosis factor alpha (TNFa) present in the supernatant of P14 CTL unstimulated and TCR retriggered in the presence or absence of either PI3K p110δ (PI3Kdi), MEK (MEKi) or AKT (AKTi) inhibitor determined by ELISA. (E) Levels of XCL1, COL1, IL-3 and IL-2 protein secreted in the supernatant of unstimulated, TCR stimulated and TCR stimulated CTL in the presence of either PI3K p110δ (PI3Kdi), MEK (MEKi) or AKT (AKTi) inhibitor assayed by mass spectrometry. Transcriptome and proteome of P14 CTL unstimulated and TCR retriggered in the presence or absence of either PI3K p110δ (PI3Kdi) or MEK (MEKi) inhibitor were characterised by RNAseq and mass spectrometry respectively. Impact of PI3K p110δ and ERK1/2 inhibition on TCR induced cytokines and chemokines mRNA and protein expression was assessed. (F, G) Heatmaps showing mRNA encoding for annotated (F) cytokines, growth factors and (G) chemokines (Cytokine activity GO:0005125 and Chemokine activity GO:0008009). (H) Heatmap of proteins annotated as cytokines, growth factors and chemokines. Heatmaps show the relative mRNA abundance or the relative protein abundance graded from low (blue) to high (red) per row. Input data for heatmaps are listed in Supplementary Datasheets 2 (F, G) and 4 (H). (I) Overlap in the number of cytokine, growth factor and chemokine mRNA regulated by both PI3K p110δ and ERK1/2. Data in (C–E) shown as the mean of three biological replicates ± standard deviation and statistical analysis is calculated by unpaired, unequal variance t-test with Welch’s correction. The P values are considered as follow: *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. ‘ns’ not statistically significant.
importance of FOXO1 in controlling T cell cell exhaustion reflected that FOXO1 controlled expression of the inhibitory receptor PD-1 (28). The current study forces a revision of this conclusion by demonstrating that FOXO1 does not directly control PD-1 expression in CD8+ T cells. Hence inhibition of PI3K p110δ, which immediately causes FOXO1 to relocalise to the nucleus to transcriptionally reprogram CTL, does not impact PD-1 expression. Moreover, there is no loss of PD-1 expression in FOXO1 null CD8+ T cells. The expression of inhibitory receptors is thus not a simple on/off FOXO1 switch but requires integration of multiple signals with evidence that the oxygen environment is particularly important (59). In terms of T cell exhaustion and the ability of PI3K p110δ to control CD8+ effector/memory T cells transition then FOXO1 control of Cldn4 and Slamf6 mRNA could be relevant as these two molecules control T cell exhaustion (26, 60, 61). However, the role of FOXO1 in enforcing T cell quiescence by controlling expression of Tgfβ, Klf2 and Ap-1 family transcription factors will also be important in regulating the effector/memory versus senescent fate of CD8+ T cells (50). Moreover, PI3K p110δ and FOXO1 control of T cell trafficking, by regulating the expression of key adhesion receptors and chemokine receptors, will also influence CD8+ T cell immune responses in vivo as will PI3K p110δ control of the production of inflammatory cytokines and chemokines that recruit and/or regulate innate immune cells.

One salient insight from the current work is the magnitude and selectivity of the effects of PI3K p110δ on the transcriptional restructuring that accompanies T cell differentiation. Hence only 6% of the TCR regulated transcripts in naïve T cells were sensitive to loss of PI3K p110δ activity and in CTL this dropped to 3%.

One notable result was that expression of the major regulatory components of the metabolic programs that control T cell growth and differentiation are not dependent on PI3K p110δ activation. In this respect, T cell metabolic programs are controlled by the transcription factor Myc and serine/threonine kinase mTORC1 (mammalian target of rapamycin complex 1) (41, 48). We have shown previously that PI3K p110δ activation is not required for mTORC1 activity in CD8+ T cells (29, 43), and the present data found no role for PI3K p110δ in Myc mRNA expression or in controlling expression of Myc targets. Nor did PI3K p110δ prevent expression of Hif1α mRNA in CD8+ T cells. In this respect, analysis of the impact of mTORC1 inhibition of CTL transcriptome identified mRNA encoding glycolytic regulators and molecules that control lipid metabolism and ribosome biogenesis as major targets for mTORC1 signalling pathways (7) whereas the data herein show these were not regulated directly by PI3K p110δ. It should be emphasised there are some common targets for mTORC1 and PI3K p110δ notably KLF2 and receptors such as CD62L and S1PR1 that control T cell trafficking (7, 29, 43). The existence of these shared targets has historically been explained using a linear model whereby PI3K p110δ controls T cell responses via mTORC1 (29). However, it is now recognised that a shared requirement for PI3K p110δ and mTORC1 activity rather reflects that these signalling molecules control pathways that can converge on a single target (43). Indeed, one key observation herein is that even the role of PI3K p110δ in controlling T cell transcriptomes cannot be ascribed to a simple linear signalling pathway. For example, the ability of PI3K p110δ to control the nuclear exclusion of FOXO1 is critical for T cell differentiation yet PI3K p110δ and PKB/AKT dependent but FOXO1 independent mechanisms are also relevant. As well the ability of PI3K p110δ to repress the activity of ERKs can also contribute to its ability to modulate T cell differentiation.

Finally, a fundamental finding from the present study was that there are differences in how PI3K p110δ inactivation impacts T cell antigen receptor activated lymphocytes as they exit quiescence versus effects in effector T cells. Effector CTL are thus far less sensitive to loss of PI3K p110δ activity than naïve T cells. Moreover, inhibition of PI3K p110δ could affect the expression of cytolytic effector molecules such as the granzymes and perforin in TCR activated naïve CD8+ T cells but not in CTL. PI3K p110δ inhibition could also selectively suppress the production of cytokines and chemokines in both naïve T cells and CTL but did not prevent degranulation and release of cytolytic molecules by CTL. These results are pertinent because when thinking of how to use PI3K p110δ inhibitors therapeutically it is important to consider whether the objective is to suppress the effector immune response or to prevent de novo immune activation. Many screens focus on how inhibitors prevent primary activation of quiescent peripheral blood derived T cells. The current study highlights how unbiased screening of both naïve and effector populations would give a better perspective on the potential therapeutic benefit of signalling inhibitors.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/geo/, GSE169436; https://www.ncbi.nlm.nih.gov/geo/, GSE169449; https://www.ncbi.nlm.nih.gov/geo/, GSE169572; http://www.proteomexchange.org/, PXD025046; http://www.proteomexchange.org/, PXD025061. ChIP-seq, and ATAC-seq datasets were previously published (50) and deposited to the NCBI GEO/SRA and can be accessed with the identifier GSE163723.

ETHICS STATEMENT

The animal study was reviewed and approved by the University Ethical Review Committee under the authorisation of the UK Home Office Animals (Scientific Procedures) Act 1986.

AUTHOR CONTRIBUTIONS

LS and DC designed the experiments. LS, AN, and MD performed the experiments. JM did the bioinformatics for the RNAseq data. LS analysed the data and produced the figures. LS and DC interpreted the results and wrote the manuscript. DC conceived the study, supervised the experiments and provided financial support. All authors contributed to the article and approved the submitted version.
FUNDING
This research was supported by a Wellcome Trust Principal Research Fellowship to DC (205023/Z/16/Z). JM was supported by an Australian NHMRC CJ Martin Early Career fellowship and JM and DC have received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement No. 705984. AN was supported by the MRC doctoral training program (MR/KS01384/1).

ACKNOWLEDGMENTS
We thank the members of the Cantrell laboratory for comments on the manuscript, Alejandro Brenes for providing us with analytic tool support, the Flow Cytometry Facility (A. Whigham, M. Lee, V. Reid, A. Gardner and R. Clarke), the biological sciences research unit at the University of Dundee, the Proteomics Facility (D. Lamont and team, Dundee), the Finnish Functional Genomics Centre and the Medical Bioinformatics Centre of Turku Biosciences that is supported by University of Turku, Abo Akademi University, Biocenter Finland and Eluxir-Finland.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.691997/full#supplementary-material

REFERENCES
1. Curtsinger JM, Mescher MF. Inflammatory Cytokines as a Third Signal for T Cell Activation. Curr Opin Immunol (2010) 22(3):333–40. doi: 10.1016/j.coi.2010.02.013
2. Cantrell D. Signaling in Lymphocyte Activation. Cold Spring Harb Perspect Biol (2015) 7(6):a018788. doi: 10.1101/cshperspect.a018788
3. Costello PS, Gallagher M, Cantrell DA. Sustained and Dynamic Inositol Lipid Metabolism Inside and Outside the Immunological Synapse. Nat Immunol (2002) 3(11):1082–9. doi: 10.1038/nai48
4. Garcon F, Patton DF, Emery JI, Hirsch E, Rottapel R, Sasaki T, et al. CD28 Provides T-Cell Costimulation and Enhances PI3K Activity at the Immune Synapse Independently of Its Capacity to Interact With the p85/p110 Heterodimer. Blood (2008) 111(3):1464–71. doi: 10.1182/blood-2007-08-108050
5. Stark AK, Chandra A, Chakraborty K, Alam R, Carbonaro V, Clark J, et al. PI3Kdelta Hyper-Activation Promotes Development of B Cells That Exacerbate Streptococcus Pneumoniae Infection in an Antibody-Independent Manner. Nat Commun (2018) 9(1):3174. doi: 10.1038/s41467-018-05674-8
6. Ross SH, Rollings C, Anderson KE, Hawkins PT, Stephens LR, Cantrell DA. Phosphoepitome Analyses of Interleukin 2 Signaling Revealed Integrated JAK Kinase-Dependent and -Independent Networks in CD8(+) T Cells. Immunity (2016) 45(3):685–700. doi: 10.1016/j.immuni.2016.07.022
7. Hękulenn J, Anderson KE, Sinclair LV, Grzes KM, Murillo AB, Hawkins PT, et al. The Cytotoxic T Cell Proteome and Its Shaping by the Kinase mTOR. Nat Immunol (2016) 17(1):104–12. doi: 10.1038/nii.3314
8. So L, Fruman DA. PI3K Signalling in B- and T-Lymphocytes: New Developments and Therapeutic Advances. Biochem J (2012) 443(3):465–81. doi: 10.1042/BJO20112092
9. Okkenhaug K, Ali K, Vanhasebroeck B. Antigen Receptor Signalling: A Distinctive Role for the p110Delta Isoform of PI3K. Trends Immunol (2007) 28(2):80–7. doi: 10.1016/j.it.2006.12.007
10. Angulo I, Vadás O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-Kinase Delta Gene Mutation Predisposes to Respiratory Infection and Airway Damage. Science (2013) 342(6160):866–71. doi: 10.1126/science.1234292
11. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-Activating Germline Mutations in the Gene Encoding the PI(3)K Catalytic Subunit p110delta Result in T Cell Senescence and Human Immunodeficiency. Nat Immunol (2014) 15(1):88–97. doi: 10.1038/ni.2771
12. Sogkas G, Fedchenko M, Dhiingra A, Jablonka A, Schmidt RE, Atschekei F. Primary Immunodeficiency Disorder Caused by Phosphoinositide 3-Kinase Delta Deficiency. J Allergy Clin Immunol (2018) 142(5):1650–3.e2. doi: 10.1016/j.jaci.2018.06.039
13. Swan DJ, Aschenbrenner D, Lamb CA, Chakraborty K, Clark J, Engelhardt KR, et al. Immunodeficiency, Autoimmune Thrombocytopenia and Enterocolitis Caused by Autosomal Recessive Deficiency of PIK3CD-Encoded Phosphoinositide 3-Kinase δ. Haematologica (2019) 104:483–6. doi: 10.3324/haematol.2018.208397
14. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Billottet C, Grandage VL, et al. Selective Inhibition of the p110delta Isoform of PI-3-Kinase Inhibits AML Cell Proliferation and Survival and Increases the Cytotoxic Effects of VP16. Oncogene (2006) 25(50):6648–59. doi: 10.1038/sj.onc.1209670
15. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors. Mol Cancer Ther (2014) 13(5):1021–31. doi: 10.1158/1535-7163.MCT-13-0639
16. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials. Mol Cancer (2019) 18(1):26. doi: 10.1038/s41602-019-0954-x
17. Eschweiler S, Ramirez-Suátegui C, King E, Chadley L, Thomas J, Wood O, et al. Immunomodulatory Effects of PI3Kδ Inhibition in Solid Tumors – Evaluation in a Randomized Phase II Trial. doi: 1021203/rs3rs-337290/v1

Supplementary Data Sheet 1 | CD8 naive and TCR activated 24 h ± inhibitor RNAseq data.
Supplementary Data Sheet 2 | Unstim and TCR stimulated 4 h CTL ± inhibitors RNAseq data.
Supplementary Data Sheet 3 | WT and FOXO1-GFP KO CTL ± inhibitor 24 h RNAseq data.
Supplementary Data Sheet 4 | Unstim and TCR stimulated 4 h CTL ± inhibitors proteomic data.

Supplementary Table 1 | mRNA changing significantly in naïve CD8+ T cells after 24 h TCR activation.
Supplementary Table 2 | mRNA changing significantly in 24 h TCR activated cells after PI3K p110δ inhibition.
Supplementary Table 3 | mRNA changing significantly in CTL after 4 h TCR retriggering.
Supplementary Table 4 | mRNA changing significantly in 4 h TCR retriggered CTL after PI3K p110δ inhibition.
Supplementary Table 5 | mRNA changing significantly in WT CTL after 24 h PI3K p110δ inhibition.
Supplementary Table 6 | mRNA changing significantly in PI3K p110δ treated FOXO1-GFP KO versus WT treated CTL.
Supplementary Table 7 | mRNA changing significantly in 4 h TCR retriggered CTL after ERK1-2 inhibition.
29. Sinclair LV, Sullivan JA, Plisch EH, Jefferis EM, Mattick J, Cho K, et al. Signal Integration by AKT Regulates CD8 T Cell Effector and Memory Differentiation. Immunity (2012) 37(4):405–14. doi: 10.1016/j.immuni.201103568

30. Oliveros JC. Venny: An Interactive Tool for Comparing Lists With Venn Diagrams. (2007). Available at: https://bioinfo.cnb.csic.es/tools/venny/venny.html

31. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analysis For RNA-sequencing and Microarray Studies. Nucleic Acids Res (2015) 43(7):e47. doi: 10.1093/nar/gkv007

32. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics (2010) 26(1):139–40. doi: 10.1093/bioinformatics/btp516

33. McCarthy DJ, Chen Y, Smyth GK. Differential Expression Analysis of Multi-factor RNA-Seq Experiments With Respect to Biological Variation. Nucleic Acids Res (2012) 40(10):4288–97. doi: 10.1093/nar/gks042

34. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast Universal RNA-Seq Aligner. Bioinformatics (2013) 29(1):15–21. doi: 10.1093/bioinformatics/bts635

35. McCarthy DJ, Chen Y, Smyth GK. Differential Expression Analysis of Multi-factor RNA-Seq Experiments With Respect to Biological Variation. Nucleic Acids Res (2012) 40(10):4288–97. doi: 10.1093/nar/gks042

36. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics (2010) 26(1):139–40. doi: 10.1093/bioinformatics/btp516

37. McCarthy DJ, Chen Y, Smyth GK. Differential Expression Analysis of Multi-factor RNA-Seq Experiments With Respect to Biological Variation. Nucleic Acids Res (2012) 40(10):4288–97. doi: 10.1093/nar/gks042

38. Lawrence M, Huber W, Pages H, Abyzoun P, Carlson M, Gentleman R, et al. Software for Computing and Annotating Genomic Ranges. PLoS Comput Biol (2013) 9(8):e1003118. doi: 10.1371/journal.pcbi.1003118

39. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analysis For RNA-sequencing and Microarray Studies. Nucleic Acids Res (2015) 43(7):e47. doi: 10.1093/nar/gkv007

40. Oliveros JC. Venny: An Interactive Tool for Comparing Lists With Venn Diagrams. (2007). Available at: https://bioinfo.cnb.csic.es/tools/venny/venny.html

41. Marchingo JM, Sinclair LV, Howden AJ, Cantrell DA. Quantitative Analysis of How Myc Controls T Cell Proteomes and Metabolic Pathways During T Cell Activation. Elife (2020) 5:e53725. doi: 10.7554/eLife.53725

42. Winiewski JR, Hein MY, Cox J, Mann M. A “Proteomic Ruler” for ProteinCopy Number and Concentration Estimation Without Spike-in Standards. Mol Cell Proteomics (2014) 13(12):3497–506. doi: 10.1074/mcp.M113.037309

43. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carrero C, Hukelmann JL, Rolf J, et al. PDK1 Regulation of mTOR and Hypoxia-Inducible Factor 1 Integrate Metabolism and Migration of CD8+ T Cells. J Exp Med (2012) 209(13):2441–53. doi: 10.1084/jem.20112607

44. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The Transcription Factor Myc Controls Metabolic Reprogramming Upon T Lymphocyte Activation. Immunity (2011) 35(6):871–82. doi: 10.1016/j.immuni.2011.09.021

45. Brewitz A, Eckhoff S, Dahling S, Quast T, Bedoui S, Krouzek R, et al. CD8+ T Cells orchestrate PD-1+CD8+ T Cell Spatial and Functional Cooperativity to Optimize Priming. Immunity (2017) 46(2):205–19. doi: 10.1016/j.immuni.2017.01.006

46. Castello F, Huang AY, Altamir-Bonnet G, Stoll S, Scheinerck C, Germain RN. Chemokines Enhance Immunity by Guiding Naive CD8+ T Cells to Sites of CD4+ T Cell-Dendritic Cell Interaction. Nature (2006) 440(7086):890–5. doi: 10.1038/nature04651

47. Leif DH, Woidky A, Oxley D, Chessa T, Hudson K, Hawkins PT, et al. P3IEkelta Forms Distinct Multipeptide Complexes at the TCR Signalingosome in Naive and Differentiated CD8+ T Cells. Front Immunol (2021) 12:631271. doi: 10.3389/fimmu.2021.631271

48. Howden AJM, Hukelmann JL, Brenes A, Spinelli L, Sinclair LV, Lamond AI, et al. Quantitative Analysis of T Cell Proteomes and Environmental Sensors During T Cell Differentiation. Immunity (2019) 20(11):1542–54. doi: 10.1016/j.immuni.2019.09.045x

49. Waugh C, Sinclair L, Finlay D, Bayascas JR, Cantrell DA. Phosphoinositide (3,4,5)-Phosphatidylinositol-3-OH Kinase and Nutrient-Sensing mTOR Pathways Control T Lymphocyte Trafficking. Nat Immunol (2008) 9(5):513–21. doi: 10.1038/ni.1603

50. Okkenhaug K, Bilancia A, Farjot G, Priddle H, Sancho S, Pesset E, et al. Impaired B and T Cell Antigen Receptor Signaling in P110 Fl-3 Kinase-Deficient Mice. Immunity (2002) 97(1):103–14. doi: 10.1016/s0899-8218(02)00142-9

51. Pincher H, Birki K, Lang R, Hengartner Z, Zinkernagel RM. Tolerance Induction in Specific T-Cell Receptor Transgenic Mice Varies With Antigen. Nature (1989) 341:559–61. doi: 10.1038/342559a0

52. Stone EL, Pepper M, Katayama CD, Kerdiles YM, Lai CY, Emslie E, et al. ICOS Coreceptor Signaling Inactivates the Transcription Factor FOXP3 to Promote TFH Cell Differentiation. Immunity (2015) 42(2):239–51. doi: 10.1016/j.immuni.2015.01.017

53. Jacob J, Baltimore D. Modelling T-Cell Memory by Genetic Marking of Memory Tcells In Vivo. Nature (1999) 399:593–7. doi: 10.1038/21208

54. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast Universal RNA-Seq Aligner. Bioinformatics (2013) 29(1):15–21. doi: 10.1093/bioinformatics/bts635

55. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: Summary Analysis Results for Multiple Tools and Samples in a Single Report. Bioinformatics (2016) 32(19):3047–8. doi: 10.1093/bioinformatics/btw354

56. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics (2010) 26(1):139–40. doi: 10.1093/bioinformatics/btp516

57. McCarthy DJ, Chen Y, Smyth GK. Differential Expression Analysis of Multi-factor RNA-Seq Experiments With Respect to Biological Variation. Nucleic Acids Res (2012) 40(4):1288–97. doi: 10.1093/nar/gkr042

58. Lawrence M, Huber W, Pages H, Abyzoun P, Carlson M, Gentleman R, et al. Software for Computing and Annotating Genomic Ranges. PLoS Comput Biol (2013) 9(8):e1003118. doi: 10.1371/journal.pcbi.1003118

59. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analysis For RNA-sequencing and Microarray Studies. Nucleic Acids Res (2015) 43(7):e47. doi: 10.1093/nar/gkv007

60. Oliveros JC. Venny: An Interactive Tool for Comparing Lists With Venn Diagrams. (2007). Available at: https://bioinfo.cnb.csic.es/tools/venny/venny.html

61. Brnetic J, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei MG, et al. A New Member of the Immunoglobulin Superfamily-CILA-4. Nature (1987) 328:267–70. doi: 10.1038/328267a0
58. Korman A, Yellin M TK. Tumor Immunotherapy: Preclinical and Clinical Activity of Anti-CTLA4 Antibodies. Curr Opin Investig Drugs (2005) 6:582–91.
59. Palazon A, Tyrakis PA, Macias D, Velica P, Randqvist H, Fitzpatrick S, et al. An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell (2017) 32(5):669–83.e5. doi: 10.1016/j.ccell.2017.10.003
60. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, et al. SLAMF6 as a Regulator of Exhausted CD8(+) T Cells in Cancer. Cancer Immunol Res (2019) 7(9):1485–96. doi: 10.1158/2326-6066.CIR-18-0664
61. Sandu I, Cerletti D, Oetiker N, Borsa M, Wagen F, Spadafora I, et al. Landscape of Exhausted Virus-Specific CD8 T Cells in Chronic LCMV Infection. Cell Rep (2020) 32(8):108078. doi: 10.1016/j.celrep.2020.108078

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Spinelli, Marchingo, Nomura, Damasio and Cantrell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.